Your browser is no longer supported. Please, upgrade your browser.
Settings
ATRA Atara Biotherapeutics, Inc. daily Stock Chart
ATRA [NASD]
Atara Biotherapeutics, Inc.
Index- P/E- EPS (ttm)-3.33 Insider Own6.00% Shs Outstand30.17M Perf Week6.16%
Market Cap467.64M Forward P/E- EPS next Y-4.14 Insider Trans-9.29% Shs Float26.52M Perf Month13.55%
Income-96.70M PEG- EPS next Q-0.97 Inst Own- Short Float16.95% Perf Quarter15.24%
Sales- P/S- EPS this Y-23.00% Inst Trans5.67% Short Ratio20.49 Perf Half Y-27.06%
Book/sh7.56 P/B2.05 EPS next Y-6.40% ROA-37.40% Target Price30.25 Perf Year-19.69%
Cash/sh7.19 P/C2.16 EPS next 5Y- ROE-39.50% 52W Range11.80 - 23.00 Perf YTD9.15%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-32.61% Beta-
Dividend %- Quick Ratio19.40 Sales past 5Y- Gross Margin- 52W Low31.36% ATR0.78
Employees96 Current Ratio19.40 Sales Q/Q- Oper. Margin- RSI (14)55.84 Volatility5.12% 5.52%
OptionableYes Debt/Eq0.00 EPS Q/Q-42.40% Profit Margin- Rel Volume0.25 Prev Close15.50
ShortableYes LT Debt/Eq0.00 EarningsAug 14 AMC Payout- Avg Volume219.28K Price15.50
Recom2.00 SMA205.08% SMA503.94% SMA200-1.56% Volume29,213 Change0.00%
Jun-22-17Resumed Jefferies Buy $30
Oct-24-16Resumed Jefferies Buy
Sep-15-16Downgrade Goldman Neutral → Sell
Dec-15-15Downgrade Citigroup Buy → Sell
Nov-18-15Resumed Goldman Neutral
Sep-25-15Initiated JMP Securities Mkt Perform
Sep-09-15Initiated Canaccord Genuity Buy $80
Jun-04-15Reiterated Jefferies Buy $43 → $47
Sep-16-17 06:13PM  Should You Buy Atara Biotherapeutics Inc (ATRA) Now? Simply Wall St.
Sep-11-17 08:00AM  Atara Biotherapeutics Receives Positive Health Canada Regulatory Feedback for ATA129 GlobeNewswire
Sep-05-17 08:00AM  Atara Biotherapeutics Receives FDA Orphan Drug Designation for ATA230 GlobeNewswire
Aug-31-17 04:15PM  Atara Biotherapeutics to Participate in Three Upcoming Investor Conferences GlobeNewswire +7.14%
Aug-25-17 07:50AM  Featured Company News Can-Fite Receives Second Milestone Payment From CKD Pharmaceuticals for Namodenoson (CF102) in South Korea ACCESSWIRE
Aug-22-17 04:35PM  Atara Biotherapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
08:00AM  Atara Biotherapeutics Expands Leadership Team with the Appointment of Dr. Kanya Rajangam as Senior Vice President and Chief Medical Officer GlobeNewswire
Aug-07-17 11:37PM  Atara Biotherapeutics reports 2Q loss Associated Press
06:36PM  Atara Biotherapeutics reports 2Q loss Associated Press
04:05PM  Atara Biotherapeutics Announces Second Quarter 2017 Financial Results and Recent Highlights GlobeNewswire
Aug-02-17 08:00AM  Atara Biotherapeutics to Present at the Canaccord Genuity 37th Annual Growth Conference GlobeNewswire
Jul-31-17 08:10AM  Atara Biotherapeutics Announces Two Presentations at MSParis2017, Including Updated, Interim Results from a Phase 1 Study of Autologous ATA188 in Patients with Progressive Multiple Sclerosis (MS) GlobeNewswire
May-24-17 08:00AM  Atara Biotherapeutics to Present at Three Upcoming Investor Conferences GlobeNewswire -5.54%
May-10-17 05:00PM  Atara Biotherapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
08:00AM  Atara Biotherapeutics Enhances Commercial Expertise with the Appointment of Dr. Derrell Porter to the Executive Leadership Team GlobeNewswire
May-05-17 05:02AM  Atara Biotherapeutics reports 1Q loss Associated Press -6.27%
May-04-17 04:15PM  Atara Biotherapeutics Announces First Quarter 2017 Financial Results and Recent Highlights GlobeNewswire
Apr-21-17 09:34AM  Biotech Movers: XBiotech, Atara, Bellicum TheStreet.com -10.58%
08:00AM  Atara Bio Announces Collaboration with Merck to Evaluate KEYTRUDA® (pembrolizumab) in Combination with ATA129 in Nasopharyngeal Carcinoma (NPC) GlobeNewswire
Apr-20-17 05:16PM  Atara Biotherapeutics shares rise on MS drug study results MarketWatch
04:20PM  Atara Bio Announces Positive Interim Results from Ongoing Phase 1 Trial of the Autologous Version of ATA188 in Patients with Primary and Secondary Progressive Multiple Sclerosis (MS) at the American Academy of Neurology (AAN) Annual Meeting 2017 GlobeNewswire
Apr-03-17 08:00AM  Atara Bio Expands Management Team, Appoints Joe Newell as Executive Vice President, Chief Technical Operations Officer GlobeNewswire
Mar-27-17 05:08PM  ATARA BIOTHERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and
Mar-17-17 12:45PM  Atara Bio's Collaborating Investigators to Present Interim Results from Phase 1 Trial of the Autologous Version of ATA188 in Patients with Progressive Multiple Sclerosis (MS) GlobeNewswire +7.51%
Mar-14-17 01:04PM  ATARA BIOTHERAPEUTICS, INC. Financials -11.01%
Mar-09-17 08:34AM  Atara Biotherapeutics reports 4Q loss Associated Press +8.38%
08:16AM  ATARA BIOTHERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
08:00AM  Atara Bio Announces Fourth Quarter and Full Year 2016 Financial Results and Recent Highlights GlobeNewswire
Feb-10-17 04:13PM  ATARA BIOTHERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers -6.52%
Feb-07-17 10:26AM  ATARA BIOTHERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
Jan-04-17 08:00AM  Atara Bio to Present at the 35th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Jan-03-17 08:00AM  Atara Bio Concludes EMA Scientific Advice and Plans to Submit Conditional Marketing Authorization Application (MAA) in Europe for Allogeneic Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes (CTL), or ATA 129, for the Treatment of E GlobeNewswire +6.16%
Dec-15-16 02:01PM  Favorite Healthcare Stocks of Billionaire Seth Klarmans Baupost Group Insider Monkey
02:01PM  Favorite Healthcare Stocks of Billionaire Seth Klarmans Baupost Group at Insider Monkey
Dec-14-16 06:15AM  Atara Biotherapeutics Inc (ATRA): Are Hedge Funds Right About This Stock? Insider Monkey -13.02%
06:15AM  Atara Biotherapeutics Inc (ATRA): Are Hedge Funds Right About This Stock? at Insider Monkey
Dec-12-16 08:00AM  Atara Bio Reaches Agreement with FDA on Design of Phase 3 Trials for its Lead Anti-Cancer Immunotherapy Program, Allogeneic Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes (CTL), or ATA 129, to Support Potential Approval in Two Se GlobeNewswire
Dec-03-16 10:30AM  Atara Bio Announces Results from Ongoing Phase 2 Trial of Allogeneic Cytomegalovirus (CMV)-specific Cytotoxic T Lymphocytes (CTL) at the American Society of Hematology (ASH) Annual Meeting 2016 GlobeNewswire
Nov-28-16 02:21PM  Atara Biotherapeutics, Inc. :ATRA-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016
Nov-04-16 08:28AM  Atara Biotherapeutics reports 3Q loss +6.32%
08:16AM  ATARA BIOTHERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
08:00AM  Atara Bio Announces Third Quarter 2016 Financial Results and Recent Highlights GlobeNewswire
Nov-03-16 09:00AM  Atara Bio's Collaborating Investigators to Present Results from Phase 2 Trial of Allogeneic Cytomegalovirus (CMV)-specific Cytotoxic T Lymphocytes (CTL) at the American Society of Hematology (ASH) Annual Meeting 2016 GlobeNewswire
Nov-02-16 09:08AM  Atara Biotherapeutics (ATRA): Moving Average Crossover Alert
Oct-27-16 09:53AM  What Falling Estimates & Price Mean for Atara Biotherapeutics (ATRA)
Oct-18-16 08:00AM  Atara Bio Granted Access to Priority Medicines (PRIME) Regulatory Support for Allogeneic Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes (CTL) for Treatment of EBV-Associated Post Transplant Lymphoproliferative Disorder (EBV-PTLD) GlobeNewswire
Oct-11-16 08:00AM  Atara Bio Receives Positive Opinion from EMA on Orphan Drug Designation for Allogeneic Cytomegalovirus (CMV)-specific Cytotoxic T Lymphocytes (CTL) for Treatment of CMV Infection in Patients with Impaired Immune Systems GlobeNewswire
Sep-29-16 06:00AM  'Mad Money' Lightning Round: Buy Red-Hot Suncoke Energy -5.27%
Sep-28-16 07:15PM  Cramer: If you're looking to invest in coal, here's my top pick at CNBC
Sep-23-16 05:17PM  ATARA BIOTHERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Sep-15-16 07:56AM  Atara Biotherapeutics Has 25% Downside -10.08%
06:13AM  Atara Biotherapeutics downgraded by Goldman
Sep-13-16 03:23PM  Atara Biotherapeutics, Inc. :ATRA-US: Earnings Analysis: Q2, 2016 By the Numbers : September 13, 2016
Sep-08-16 04:05PM  Atara Bio to Participate in the Morgan Stanley Global Healthcare Conference GlobeNewswire
Aug-08-16 04:51PM  A Handful of Biotech Stocks Plunge After Disappointing Results Benzinga -9.37%
08:07AM  Atara Biotherapeutics reports 2Q loss
08:06AM  ATARA BIOTHERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
08:00AM  Atara Bio Announces Second Quarter 2016 Financial Results and Recent Highlights GlobeNewswire
Aug-04-16 04:05PM  Atara Bio to Present at the Canaccord Genuity 36th Annual Growth Conference GlobeNewswire
Jul-18-16 08:00AM  AMAG Pharmaceuticals CEO William Heiden Elected to PhRMA Board of Directors GlobeNewswire
Jul-12-16 08:00AM  Atara Bio Doses First Patient in Multi-Center Expanded Access Protocol for Study of Allogeneic Epstein-Barr Virus Specific Cytotoxic T-lymphocytes (EBV-CTLs) in EBV-Associated Lymphomas and Lymphoproliferative Disorders GlobeNewswire
Jun-24-16 04:32PM  ATARA BIOTHERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Jun-23-16 09:30AM  Atara Bio Receives Advanced Therapy Medicinal Product Classification for Allogeneic Epstein-Barr Virus Specific Cytotoxic T-lymphocytes (EBV-CTLs) from European Medicines Agency (EMA) GlobeNewswire
Jun-15-16 04:05PM  Atara Bio to Present at the JMP Securities Life Sciences Conference GlobeNewswire
Jun-06-16 06:30PM  Atara Bio Announces Clinical Trial Results for the Treatment of EBV+ Nasopharyngeal Carcinoma using Allogeneic Epstein-Barr Virus Cytotoxic T-Lymphocyte Product Candidate GlobeNewswire +6.49%
Jun-03-16 07:12AM  Biotech picks: ALDR & RDHE -5.02%
Jun-02-16 12:58PM  Atara Biotherapeutics, Inc. :ATRA-US: Earnings Analysis: Q1, 2016 By the Numbers : June 2, 2016 +5.75%
May-31-16 04:05PM  Atara Bio to Present at Three Upcoming Investor Conferences GlobeNewswire
May-18-16 07:25PM  UPDATE: New Abstract Links -- Atara Bio Announces Presentations of Clinical Data from EBV-CTL and STM 434 Product Candidates at the Upcoming 2016 American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
05:00PM  Atara Bio Announces Presentations of Clinical Data from EBV-CTL and STM 434 Product Candidates at the Upcoming 2016 American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
May-09-16 08:00AM  Atara Bios Collaborating Investigators to Present Clinical Data on EBV-CTL at 2016 American Transplant Congress GlobeNewswire +8.85%
May-06-16 04:53PM  ATARA BIOTHERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
May-05-16 03:31PM  Atara Biotherapeutics reports 1Q loss
11:08AM  ATARA BIOTHERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
08:00AM  Atara Bio Announces First Quarter 2016 Financial Results and Recent Highlights GlobeNewswire
Apr-19-16 05:15PM  Atara Bios Collaborator QIMR Berghofer Medical Research Institute Reports Positive Clinical Data for T Cell Immunotherapy in Nasopharyngeal Cancer (NPC), a Solid Tumor GlobeNewswire
Apr-06-16 08:00AM  Atara Bio to Present at the 15th Annual Needham Healthcare Conference GlobeNewswire +15.24%
Mar-28-16 04:33PM  Atara Bio Announces Participation in Two Upcoming Immuno-Oncology Conferences at noodls
04:05PM  Atara Bio Announces Participation in Two Upcoming Immuno-Oncology Conferences GlobeNewswire
Mar-23-16 09:32AM  Atara Bio Receives EMA Orphan Drug Designation for Allogeneic Epstein-Barr Virus Specific Cytotoxic T-lymphocytes to Treat Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disorder at noodls -9.14%
09:15AM  Atara Bio Receives EMA Orphan Drug Designation for Allogeneic Epstein-Barr Virus Specific Cytotoxic T-lymphocytes to Treat Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disorder GlobeNewswire
Mar-16-16 04:45PM  Atara Bio Announces Collaborating Investigators to Present Data from a Late Breaking Abstract at the American Association for Cancer Research (AACR) Annual Meeting GlobeNewswire -5.33%
Mar-04-16 05:32PM  ATARA BIOTHERAPEUTICS, INC. Files SEC form 10-K, Annual Report -13.22%
Mar-03-16 04:49PM  Atara Biotherapeutics reports 4Q loss -6.11%
04:24PM  ATARA BIOTHERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
Feb-29-16 08:00AM  Atara Bio to Present at the Cowen and Company 36th Annual Health Care Conference GlobeNewswire
Feb-16-16 06:14AM  ATARA BIOTHERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Feb-15-16 03:20PM  Celsion (CLSN) Provides Pipeline Update, GEN-1 in Focus
10:28AM  Billionaire Seth Klarmans Top Biotech Stock Picks at Insider Monkey
Feb-12-16 03:20PM  Aegerion Announces Reduction in Workforce to Cut Costs +9.99%
Feb-11-16 09:30AM  New Strong Buy Stocks for February 11th -5.66%
Feb-08-16 08:00AM  Atara Bio Receives FDA Orphan Drug Designation for EBV-CTL to Treat Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disorder (EBV-PTLD) -8.57%
Feb-04-16 01:40PM  Novo Nordisk Posts In Line Q4 Earnings, Tops Revenues +5.49%
Feb-03-16 12:40PM  Bio-Techne (TECH) Q2 Earnings Match, Sales Beat Estimates
Jan-27-16 08:04AM  Atara Bio Announces Participation in Two Upcoming Investor Conferences at noodls
08:00AM  Atara Bio Announces Participation in Two Upcoming Investor Conferences GlobeNewswire
Jan-12-16 08:54AM  Halozyme Therapeutics (HALO) in Focus: Stock Tumbles 16.7% +8.10%
Jan-04-16 04:05PM  Atara Bio to Present at the 34th Annual J.P. Morgan Healthcare Conference GlobeNewswire -8.94%
Dec-29-15 08:55AM  Top Analyst Upgrades and Downgrades on Tuesday: Albemarle, Atara, Chimerix, IHS, NetApp, Pure Storage and More at 24/7 Wall St. +8.65%
Dec-21-15 08:15AM  Atara Biotherapeutics (ATRA) Jumps: Stock Moves Up 6%
Atara Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of muscle wasting conditions and oncology. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. The company is also developing STM 434, a targeted therapy for ovarian cancer and other solid tumors; and a pipeline of product candidates that are in preclinical development. Atara Biotherapeutics, Inc. was founded in 2012 and is headquartered in Brisbane, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Haqq ChristopherEVP, R&D & Chief Scientific OfSep 15Sale15.306,00091,800349,305Sep 18 05:46 PM
Ciechanover Isaac E.Chief Executive OfficerSep 07Sale14.982,20032,956437,378Sep 08 04:02 PM
Ciechanover Isaac E.Chief Executive OfficerSep 06Sale15.052,20033,110439,578Sep 08 04:02 PM
Ciechanover Isaac E.Chief Executive OfficerAug 23Sale13.512,20029,722441,778Aug 24 05:10 PM
Ciechanover Isaac E.Chief Executive OfficerAug 22Sale13.562,20029,832443,978Aug 24 05:10 PM
Soffer GadEVP & Chief Strategy OfficerAug 16Sale14.532,46435,802259,090Aug 17 05:37 PM
Gallagher Carol GiltnerDirectorAug 16Sale14.301,18416,931108,556Aug 17 05:38 PM
MCGRATH JOHNEVP & Chief Financial OfficerAug 16Sale14.392,10030,219120,957Aug 17 05:36 PM
Clark Mitchall G.EVP & Chief R & QA OfficerAug 16Sale14.333,02143,291159,130Aug 17 05:34 PM
Clark Mitchall G.EVP & Chief R & QA OfficerAug 15Option Exercise0.007,2110162,151Aug 17 05:34 PM
Ciechanover Isaac E.Chief Executive OfficerAug 15Option Exercise0.005,9080737,767Aug 17 05:34 PM
MCGRATH JOHNEVP & Chief Financial OfficerAug 15Option Exercise0.007,6970125,157Aug 17 05:36 PM
Fust Matthew KDirectorAug 15Option Exercise0.001,603028,901Aug 17 05:41 PM
Soffer GadEVP & Chief Strategy OfficerAug 15Option Exercise0.004,1450261,554Aug 17 05:37 PM
Haqq ChristopherEVP, R&D & Chief Scientific OfAug 15Option Exercise0.008290362,909Aug 17 05:35 PM
Gallagher Carol GiltnerDirectorAug 15Option Exercise0.002,3660109,740Aug 17 05:38 PM
Soffer GadEVP & Chief Strategy OfficerAug 15Sale15.007,000105,000257,409Aug 17 05:37 PM
MCGRATH JOHNEVP & Chief Financial OfficerAug 15Sale14.232,10029,883123,057Aug 17 05:36 PM
Haqq ChristopherEVP, R&D & Chief Scientific OfAug 15Sale14.757,604112,159355,305Aug 17 05:35 PM
Ciechanover Isaac E.Chief Executive OfficerAug 11Sale14.582,20032,076446,178Aug 14 07:23 PM
Ciechanover Isaac E.Chief Executive OfficerAug 10Sale14.752,20032,450448,378Aug 14 07:23 PM
Ciechanover Isaac E.Chief Executive OfficerJul 25Sale16.032,70043,283450,578Jul 26 04:52 PM
Ciechanover Isaac E.Chief Executive OfficerJul 24Sale16.942,80047,421453,278Jul 26 04:52 PM
Haqq ChristopherEVP, R&D & Chief Scientific OfJul 17Sale14.926,00089,520362,080Jul 18 04:24 PM
Haqq ChristopherEVP, R&D & Chief Scientific OfJun 15Sale12.656,00075,900368,080Jun 16 04:47 PM
Gallagher Carol GiltnerDirectorJun 09Sale13.151,00013,150107,374Jun 12 05:29 PM
Ciechanover Isaac E.Chief Executive OfficerMay 31Sale13.263,45045,747456,078May 31 07:44 PM
Ciechanover Isaac E.Chief Executive OfficerMay 30Sale13.443,45046,368459,528May 31 07:44 PM
Ciechanover Isaac E.Chief Executive OfficerMay 18Sale14.942,40035,856462,978May 19 04:05 PM
Ciechanover Isaac E.Chief Executive OfficerMay 17Sale14.882,40035,712465,378May 19 04:05 PM
MCGRATH JOHNEVP & Chief Financial OfficerMay 16Sale15.272,00030,540117,460May 17 05:01 PM
Gallagher Carol GiltnerDirectorMay 16Sale15.251,18418,056103,374May 17 05:01 PM
Soffer GadEVP & Chief Strategy OfficerMay 16Sale15.195,67486,188264,409May 17 04:56 PM
Clark Mitchall G.EVP & Chief R & QA OfficerMay 16Sale15.253,87359,063153,000May 17 04:57 PM
Clark Mitchall G.EVP & Chief R & QA OfficerMay 15Option Exercise0.007,2120156,873May 17 04:57 PM
MCGRATH JOHNEVP & Chief Financial OfficerMay 15Option Exercise0.008,6330121,460May 17 05:01 PM
Fust Matthew KDirectorMay 15Option Exercise0.001,602022,298May 17 05:00 PM
Ciechanover Isaac E.Chief Executive OfficerMay 15Option Exercise0.005,9080731,859May 17 04:59 PM
Gallagher Carol GiltnerDirectorMay 15Option Exercise0.002,3660104,558May 17 05:01 PM
Haqq ChristopherEVP, R&D & Chief Scientific OfMay 15Option Exercise0.008290381,684May 17 04:58 PM
Soffer GadEVP & Chief Strategy OfficerMay 15Option Exercise0.0010,5560270,083May 17 04:56 PM
MCGRATH JOHNEVP & Chief Financial OfficerMay 15Sale14.952,00029,900119,460May 17 05:01 PM
Haqq ChristopherEVP, R&D & Chief Scientific OfMay 15Sale14.997,604113,984374,080May 17 04:58 PM
Soffer GadEVP & Chief Strategy OfficerMay 15Sale15.137,000105,910259,527May 17 04:56 PM
Ciechanover Isaac E.Chief Executive OfficerApr 26Sale17.783,60064,008467,778Apr 26 07:34 PM
Ciechanover Isaac E.Chief Executive OfficerApr 25Sale17.333,60062,397471,378Apr 26 07:34 PM
Haqq ChristopherEVP, R&D & Chief Scientific OfApr 17Sale17.286,000103,680380,855Apr 19 04:29 PM
Ciechanover Isaac E.Chief Executive OfficerApr 11Sale16.994,20071,358474,978Apr 12 04:20 PM
Ciechanover Isaac E.Chief Executive OfficerApr 10Sale17.083,00051,240479,178Apr 12 04:20 PM
Ciechanover Isaac E.Chief Executive OfficerMar 28Sale19.093,60068,728482,178Mar 28 08:13 PM
Ciechanover Isaac E.Chief Executive OfficerMar 27Sale20.3412,400252,216485,778Mar 28 08:13 PM
MCGRATH JOHNEVP & Chief Financial OfficerMar 23Sale21.086,500137,020112,827Mar 23 08:06 PM
MCGRATH JOHNEVP & Chief Financial OfficerMar 22Sale20.277,500152,025119,327Mar 23 08:06 PM
Ciechanover Isaac E.Chief Executive OfficerMar 17Sale19.8320,000396,576498,178Mar 20 06:50 PM
Ciechanover Isaac E.Chief Executive OfficerMar 16Sale18.5410,800200,232518,178Mar 20 06:50 PM
Haqq ChristopherEVP, R&D & Chief Scientific OfMar 15Sale19.606,000117,600386,855Mar 17 05:07 PM
Soffer GadEVP & Chief Strategy OfficerMar 10Sale20.002,50050,000266,527Mar 13 05:42 PM
MCGRATH JOHNEVP & Chief Financial OfficerMar 10Sale20.0024,000480,000126,827Mar 10 07:57 PM
MCGRATH JOHNEVP & Chief Financial OfficerFeb 21Sale15.149,000136,260150,827Feb 22 05:32 PM
Clark Mitchall G.EVP & Chief R & QA OfficerFeb 16Sale15.963,05948,822149,661Feb 16 08:09 PM
Ciechanover Isaac E.Chief Executive OfficerFeb 16Sale15.572,40037,368348,978Feb 16 08:08 PM
Soffer GadEVP & Chief Strategy OfficerFeb 16Sale15.627,273113,604269,027Feb 16 08:10 PM
Gallagher Carol GiltnerDirectorFeb 16Sale16.101,18319,046102,192Feb 16 08:12 PM
Gallagher Carol GiltnerDirectorFeb 15Option Exercise0.002,3650103,375Feb 16 08:12 PM
Fust Matthew KDirectorFeb 15Option Exercise0.001,603020,696Feb 16 08:10 PM
MCGRATH JOHNEVP & Chief Financial OfficerFeb 15Option Exercise0.0010,5010159,827Feb 16 08:11 PM
Haqq ChristopherEVP, R&D & Chief Scientific OfFeb 15Option Exercise0.008290400,459Feb 16 08:08 PM
Soffer GadEVP & Chief Strategy OfficerFeb 15Option Exercise0.0013,7620276,300Feb 16 08:10 PM
Ciechanover Isaac E.Chief Executive OfficerFeb 15Option Exercise0.005,9070725,951Feb 16 08:08 PM
Clark Mitchall G.EVP & Chief R & QA OfficerFeb 15Option Exercise0.007,2110152,720Feb 16 08:09 PM
Haqq ChristopherEVP, R&D & Chief Scientific OfFeb 15Sale15.497,604117,786392,855Feb 16 08:08 PM
Ciechanover Isaac E.Chief Executive OfficerFeb 15Sale15.542,40037,296351,378Feb 16 08:08 PM
Soffer GadEVP & Chief Strategy OfficerFeb 14Sale15.227,000106,540262,538Feb 16 08:10 PM
Soffer GadEVP & Chief Strategy OfficerFeb 10Sale15.476,27497,029269,538Feb 13 06:15 PM
Haqq ChristopherEVP, R&D & Chief Scientific OfFeb 09Sale15.4613,975216,054399,630Feb 10 06:23 PM
Turner Heather DEVP, General Counsel & Sec.Feb 09Sale15.7212,215192,06786,142Feb 10 04:12 PM
Ciechanover Isaac E.Chief Executive OfficerFeb 03Sale13.872,40033,288353,778Feb 06 05:29 PM
Ciechanover Isaac E.Chief Executive OfficerFeb 02Sale13.452,40032,280356,178Feb 06 05:29 PM
Ciechanover Isaac E.Chief Executive OfficerJan 18Sale14.472,40034,728358,578Jan 19 04:34 PM
Haqq ChristopherEVP, R&D & Chief Scientific OfJan 17Sale14.276,00085,620364,105Jan 18 07:52 PM
Ciechanover Isaac E.Chief Executive OfficerJan 17Sale14.083,60050,688360,978Jan 19 04:34 PM
Ciechanover Isaac E.Chief Executive OfficerJan 06Sale17.106,000102,600364,578Jan 09 04:17 PM
Ciechanover Isaac E.Chief Executive OfficerJan 05Sale16.362,40039,264370,578Jan 09 04:17 PM
Ciechanover Isaac E.Chief Executive OfficerDec 23Sale15.252,40036,600372,978Dec 23 06:52 PM
Ciechanover Isaac E.Chief Executive OfficerDec 22Sale15.202,40036,473375,378Dec 23 06:52 PM
Haqq ChristopherChief Medical OfficerDec 15Sale15.406,00092,400370,105Dec 15 07:28 PM
Ciechanover Isaac E.Chief Executive OfficerDec 07Sale17.303,60062,280377,778Dec 08 05:16 PM
Ciechanover Isaac E.Chief Executive OfficerDec 06Sale18.553,60066,780381,378Dec 08 05:16 PM
Ciechanover Isaac E.Chief Executive OfficerNov 23Sale18.653,60067,142384,978Nov 23 08:13 PM
Ciechanover Isaac E.Chief Executive OfficerNov 22Sale18.218,400152,964388,578Nov 23 08:13 PM
Haqq ChristopherChief Medical OfficerNov 21Sale17.857,068126,164376,105Nov 22 06:40 PM
Soffer GadChief Operating OfficerNov 17Sale18.411,48027,247230,812Nov 22 05:31 PM
Gallagher Carol GiltnerDirectorNov 16Sale19.351,18422,91099,010Nov 17 04:51 PM
Soffer GadChief Operating OfficerNov 16Sale19.277,136137,511232,292Nov 16 08:17 PM
Clark Mitchall G.Chief R & QA OfficerNov 16Sale19.532,99558,49295,187Nov 17 04:28 PM
Clark Mitchall G.Chief R & QA OfficerNov 15Option Exercise0.007,212098,182Nov 17 04:28 PM
Soffer GadChief Operating OfficerNov 15Option Exercise0.0013,7610239,428Nov 16 08:17 PM
Haqq ChristopherChief Medical OfficerNov 15Option Exercise0.008290384,777Nov 17 04:53 PM
Gallagher Carol GiltnerDirectorNov 15Option Exercise0.002,3660100,194Nov 17 04:51 PM
Fust Matthew KDirectorNov 15Option Exercise0.001,602017,093Nov 17 04:30 PM